NASDAQ:COGT Cogent Biosciences (COGT) Stock Price, News & Analysis $8.24 -0.70 (-7.83%) (As of 07/2/2024 ET) Add Compare Share Share Today's Range$8.07▼$9.0450-Day Range$6.01▼$9.0452-Week Range$3.67▼$13.36Volume822,693 shsAverage Volume1.80 million shsMarket Capitalization$787.83 millionP/E RatioN/ADividend YieldN/APrice Target$14.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Cogent Biosciences alerts: Email Address Cogent Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside78.0% Upside$14.67 Price TargetShort InterestBearish14.98% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.63Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.19) to ($2.04) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.91 out of 5 starsMedical Sector823rd out of 914 stocksPharmaceutical Preparations Industry387th out of 433 stocks 3.4 Analyst's Opinion Consensus RatingCogent Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCogent Biosciences has only been the subject of 3 research reports in the past 90 days.Read more about Cogent Biosciences' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.98% of the outstanding shares of Cogent Biosciences have been sold short.Short Interest Ratio / Days to CoverCogent Biosciences has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.Change versus previous monthShort interest in Cogent Biosciences has recently decreased by 0.56%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCogent Biosciences does not currently pay a dividend.Dividend GrowthCogent Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for COGT. Previous Next 2.6 News and Social Media Coverage News SentimentCogent Biosciences has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Cogent Biosciences this week, compared to 2 articles on an average week.Search Interest3 people have searched for COGT on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Cogent Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cogent Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.92% of the stock of Cogent Biosciences is held by insiders.Read more about Cogent Biosciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cogent Biosciences are expected to grow in the coming year, from ($2.19) to ($2.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cogent Biosciences is -3.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cogent Biosciences is -3.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCogent Biosciences has a P/B Ratio of 3.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cogent Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the Markets[Breakthrough] The "Drug Smuggler" Curing Brain Disease?This small, under-the-radar firm has cracked the code with its proprietary "Drug Smuggler" platform. This revolutionary delivery technology could unlock a universe of new therapies for Alzheimer's, Parkinson's and other neurodegenerative diseases.Don't miss out - get the full story on this game-changing biotech play >>> About Cogent Biosciences Stock (NASDAQ:COGT)Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Read More COGT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart COGT Stock News HeadlinesJuly 1 at 2:24 AM | americanbankingnews.comAnalysts Set Cogent Biosciences, Inc. (NASDAQ:COGT) Price Target at $14.67June 28, 2024 | americanbankingnews.comCogent Biosciences (NASDAQ:COGT) Rating Reiterated by Needham & Company LLCJuly 2, 2024 | StockEarnings (Ad)Re: We’re giving you all this for less than a pair of socksThe Only Trading Tool You'll Need This Year Forget juggling multiple subscriptions and confusing indicators... Our all-in-one Premium Membership gives you everything you need to potentially profit in any market. Members have seen gains of 76.2%, 85.6%, and even 111.3% on single trades. This July 4th, get 12 months of access for just $4. June 23, 2024 | seekingalpha.comCogent Biosciences: Inflection Year Directly AheadJune 23, 2024 | americanbankingnews.comCogent Biosciences (NASDAQ:COGT) Trading 5.1% Higher June 14, 2024 | globenewswire.comCogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)May 23, 2024 | globenewswire.comCogent Biosciences Appoints Cole Pinnow as Chief Commercial OfficerMay 23, 2024 | globenewswire.comCogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual MeetingJuly 2, 2024 | StockEarnings (Ad)Re: We’re giving you all this for less than a pair of socksThe Only Trading Tool You'll Need This Year Forget juggling multiple subscriptions and confusing indicators... Our all-in-one Premium Membership gives you everything you need to potentially profit in any market. Members have seen gains of 76.2%, 85.6%, and even 111.3% on single trades. This July 4th, get 12 months of access for just $4. May 17, 2024 | investing.comCogent Biosciences Inc (COGT)May 13, 2024 | finance.yahoo.comWe Think Cogent Biosciences (NASDAQ:COGT) Can Afford To Drive Business GrowthMay 8, 2024 | markets.businessinsider.comBuy Rating on Cogent Biosciences Backed by Strong Financials and Promising Drug TrialsMay 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Clover Health Investments (CLOV), Cogent Biosciences (COGT) and Adaptive Biotechnologies (ADPT)May 7, 2024 | markets.businessinsider.comBuy Recommendation for Cogent Biosciences Based on Promising Clinical Trials and Market PositionMay 7, 2024 | finance.yahoo.comCogent Biosciences Reports First Quarter 2024 Financial ResultsApril 18, 2024 | prnewswire.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cogent Biosciences, Inc. (NASDAQ: COGT)April 9, 2024 | globenewswire.comCogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 InhibitorMarch 16, 2024 | finance.yahoo.comCOGT Apr 2024 7.500 callMarch 14, 2024 | insidermonkey.com5 Best Biotech Stocks To Buy Under $20February 28, 2024 | finance.yahoo.comCOGT Reports Full Year 2023 Financial Results and Business HighlightsFebruary 27, 2024 | msn.comBaird Downgrades Cogent Biosciences (COGT)February 26, 2024 | msn.comCogent Biosciences GAAP EPS of -$0.63February 26, 2024 | globenewswire.comCogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsFebruary 23, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cogent Biosciences as Bezuclastinib Showcases Strong Market PotentialFebruary 23, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT), Lantheus (LNTH) and Ardelyx (ARDX)February 22, 2024 | msn.comCogent Biosciences stock jumps on Phase 2 data for bezuclastinibFebruary 22, 2024 | globenewswire.comCogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic MastocytosisSee More Headlines Receive COGT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cogent Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/02/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:COGT CUSIPN/A CIK1460329 Webwww.cogint.com Phone(617) 945-5576FaxN/AEmployees164Year FoundedN/APrice Target and Rating Average Stock Price Target$14.67 High Stock Price Target$20.00 Low Stock Price Target$8.00 Potential Upside/Downside+76.7%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-192,410,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-91.56% Return on Assets-55.20% Debt Debt-to-Equity RatioN/A Current Ratio12.05 Quick Ratio12.05 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.30 per share Price / Book3.61Miscellaneous Outstanding Shares95,610,000Free Float89,953,000Market Cap$793.56 million OptionableOptionable Beta1.71 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key ExecutivesMr. Andrew R. Robbins M.B.A. (Age 48)President, CEO & Director Comp: $1.06MDr. John Edward Robinson Ph.D. (Age 49)Chief Scientific Officer Comp: $749.89kDr. Jessica Sachs M.D. (Age 49)Chief Medical Officer Comp: $773.92kMr. John L. Green C.A. (Age 44)CPA, CFO & Principal Accounting Officer Comp: $763.99kMr. Brad BarnettChief Technology OfficerChristi WaarichSenior Director of Investor RelationsMr. Evan D. Kearns J.D. (Age 44)Chief Legal Officer & Corporate Secretary Ms. Erin SchellhammerChief People OfficerMr. Dana R. Martin Pharm.D.Senior VP of Medical Affairs & Chief Patient OfficerBrad FellSenior Vice President of ChemistryMore ExecutivesKey CompetitorsImmunomeNASDAQ:IMNMAytu BioPharmaNASDAQ:AYTUCorcept TherapeuticsNASDAQ:CORTHUTCHMEDNASDAQ:HCMBiohavenNYSE:BHVNView All CompetitorsInstitutional OwnershipFarallon Capital Management LLCBought 445,000 shares on 5/24/2024Ownership: 0.483%Redmile Group LLCBought 1,048,580 shares on 5/16/2024Ownership: 4.145%Janus Henderson Group PLCBought 2,083,065 shares on 5/16/2024Ownership: 2.196%Kennedy Capital Management LLCBought 385,315 shares on 5/16/2024Ownership: 0.738%California State Teachers Retirement SystemBought 8,804 shares on 5/16/2024Ownership: 0.067%View All Institutional Transactions COGT Stock Analysis - Frequently Asked Questions Should I buy or sell Cogent Biosciences stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cogent Biosciences in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" COGT shares. View COGT analyst ratings or view top-rated stocks. What is Cogent Biosciences' stock price target for 2024? 7 analysts have issued 12 month price targets for Cogent Biosciences' shares. Their COGT share price targets range from $8.00 to $20.00. On average, they expect the company's stock price to reach $14.67 in the next twelve months. This suggests a possible upside of 78.0% from the stock's current price. View analysts price targets for COGT or view top-rated stocks among Wall Street analysts. How have COGT shares performed in 2024? Cogent Biosciences' stock was trading at $5.88 at the beginning of 2024. Since then, COGT stock has increased by 40.1% and is now trading at $8.24. View the best growth stocks for 2024 here. When is Cogent Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our COGT earnings forecast. How were Cogent Biosciences' earnings last quarter? Cogent Biosciences, Inc. (NASDAQ:COGT) released its earnings results on Tuesday, May, 7th. The technology company reported ($0.62) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by $0.11. What ETFs hold Cogent Biosciences' stock? ETFs with the largest weight of Cogent Biosciences (NASDAQ:COGT) stock in their portfolio include Tema Oncology ETF (CANC) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Invesco Dorsey Wright Healthcare Momentum ETF (PTH). What other stocks do shareholders of Cogent Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cogent Biosciences investors own include Corbus Pharmaceuticals (CRBP), Visa (V), Viveve Medical (VIVE), Red Violet (RDVT), Freeport-McMoRan (FCX), HP (HPQ), Nutanix (NTNX), OPKO Health (OPK), STMicroelectronics (STM) and Actinium Pharmaceuticals (ATNM). How do I buy shares of Cogent Biosciences? Shares of COGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:COGT) was last updated on 7/2/2024 by MarketBeat.com Staff From Our PartnersRe: We’re giving you all this for less than a pair of socksThe Only Trading Tool You'll Need This Year Forget juggling multiple subscriptions and confusing indicator...StockEarnings | Sponsored25th AmendmentIt's not surprising that talk of invoking the 25th Amendment (to remove Biden from office) has surfaced.Stansberry Research | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredBuy this small stock before coming AI Tidal WaveThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of ne...Chaikin Analytics | Sponsored270x more lucrative than NVIDIA???If you've missed out on NVIDIA's recent 1,600% run... Don't worry. Because there's one AI stock that cou...Behind the Markets | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cogent Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free COGT Stock Alerts